Graves' disease, rheumatoid arthritis, and anti-tumor necrosis factor-alpha therapy.
Shin
Jae Il
JI
Kim
Min Jung
MJ
Lee
Jae Seung
JS
D000068879:Adalimumab; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000009:adverse effects; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D001323:Autoantibodies / Q000378:metabolism; D015551:Autoimmunity / Q000187:drug effects / Q000276:immunology; D003429:Cross Reactions / Q000187:drug effects / Q000276:immunology; D000068800:Etanercept; D005260:Female; D006111:Graves Disease / Q000139:chemically induced* / Q000276:immunology / Q000503:physiopathology; D006801:Humans; D007049:Iatrogenic Disease / Q000517:prevention & control; D007074:Immunoglobulin G / Q000009:adverse effects; D007166:Immunosuppressive Agents / Q000009:adverse effects; D008991:Monitoring, Physiologic; D018124:Receptors, Tumor Necrosis Factor; D013961:Thyroid Gland / Q000187:drug effects / Q000276:immunology / Q000503:physiopathology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D001323:Autoantibodies; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab; D000068800:Etanercept